Chemotherapy and Drug Resistance in Schistosomiasis,Fascioliasis and Tapeworm Infections

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-1-59745-180-2_45
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis

  2008cited by this paper
• Characterization of two classes of benzodiazepine binding sites in Schistosoma mansoni

  2007cited by this paper
• Dose-confirmation studies of the cestocidal activity of pyrantel pamoate paste in horses.

  2006cited by this paper
• Fasciola hepatica: Tegumental surface changes in adult and juvenile flukes following treatment in vitro with the sulphoxide metabolite of triclabendazole (Fasinex)

  2004cited by this paper
• Central effects in man of the novel schistosomicidal benzodiazepine meclonazepam

  2004cited by this paper
• Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment.

  2004cited by this paper
• Schistosomiasis control: keep taking the tablets.

  2004cited by this paper
• Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control

  2004cited by this paper
• Secondary and primary murine alveolar echinococcosis: combined albendazole/nitazoxanide chemotherapy exhibits profound anti-parasitic activity.

  2004cited by this paper
• The relationship between tegumental disruption and muscle contraction inSchistosoma mansoni exposed to various compounds

  2004cited by this paper
• Lack of evidence for an antischistosomal activity of myrrh in experimental animals.

  2004cited by this paper
• Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates.

  2004cited by this paper
• Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire

  2003cited by this paper
• Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections.

  2003cited by this paper
• Efficacy of Praziquantel and Ro 15-5458, a 9-Acridanone-hydrazone Derivative, against Schistosoma haematobium

  2003cited by this paper
• Efficacy of an ivermectin-praziquantel combination in equids against bots and tapeworms

  2003cited by this paper
• Drugs for the control of parasitic diseases: current status and development in schistosomiasis.

  2003cited by this paper
• Identification of human cytochrome P450s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data

  2003cited by this paper
• Combination Chemotherapy of Schistosomiasis in Laboratory Studies and Clinical Trials

  2003cited by this paper
• Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa.

  2003cited by this paper
• Action starts now to control disease due to schistosomiasis and soil-transmitted helminthiasis.

  2003cited by this paper
• Invasion of skin by schistosome cercariae: some neglected facts.

  2003cited by this paper
• Creation by mutagenesis of a mammalian Ca(2+) channel beta subunit that confers praziquantel sensitivity to a mammalian Ca(2+) channel.

  2003cited by this paper
• Sustainable schistosomiasis control--the way forward.

  2003cited by this paper
• Sequence and level of endogenous expression of calcium channel beta subunits in Schistosoma mansoni displaying different susceptibilities to praziquantel.

  2003cited by this paper
• Changing behaviour in the common horse tapeworm.

  2003cited by this paper
• Specific sites in the Beta Interaction Domain of a schistosome Ca2+ channel β subunit are key to its role in sensitivity to the anti-schistosomal drug praziquantel

  2003cited by this paper
• Observations on clinical efficacy of albendazole emulsion in 264 cases of hepatic cystic echinococcosis.

  2003cited by this paper
• Benzimidazole treatment of cystic echinococcosis.

  2003cited by this paper
• Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers

  2002cited by this paper
• Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia.

  2002cited by this paper
• The global epidemiological situation of schistosomiasis and new approaches to control and research.

  2002cited by this paper
• A combined medical and surgical approach to hydatid disease: 12 years' experience at the Hospital for Tropical Diseases, London.

  2002cited by this paper
• New policies for using anthelmintics in high risk groups.

  2002cited by this paper
• Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal.

  2002cited by this paper
• Invasion of skin by Schistosoma cercariae.

  2002cited by this paper
• Resistance of Schistosoma mansoni to praziquantel: is there a problem?

  2002cited by this paper
• Adult worm tegumental damage and egg-granulomas in praziquantel-resistant and -susceptible Schistosoma mansoni treated in vivo.

  2002cited by this paper
• Sustainable use of anthelmintics in grazing animals

  2002cited by this paper
• A praziquantel-ineffective fascioliasis case successfully treated with triclabendazole.

  2002cited by this paper
• Praziquantel-induced tegumental damage in vitro is diminished in schistosomes derived from praziquantel-resistant infections

  2001cited by this paper
• Biological characteristics of praziquantel-resistant and -susceptible isolates of Schistosoma mansoni.

  2001cited by this paper
• Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence

  2001cited by this paper
• Schistosome calcium channel beta subunits. Unusual modulatory effects and potential role in the action of the antischistosomal drug praziquantel.

  2001cited by this paper
• Activity of oxyclozzanide, nitroxynil, clorsulon and albendazole against adult triclabendazole resistant Fasciola hepatica

  2001cited by this paper
• In vitro responses of praziquantel-resistant and -susceptible Schistosoma mansoni to praziquantel.

  2001cited by this paper
• Praziquantel--quality, dosages and markers of resistance.

  2001cited by this paper
• Mirazid: A New Schistosomicidal Drug

  2001cited by this paper
• The efficacy of praziquantel against Schistosoma mansoni infection in Ndombo, northern Senegal.

  2001cited by this paper
• Replacing oxamniquine by praziquantel against Schistosoma mansoni infection in a rural community from the sugar-cane zone of Northeast Brazil: an epidemiological follow-up.

  2001cited by this paper
• Sodium excretion and cardiovascular mortality

  2001cited by this paper
• Refugia--overlooked as perhaps the most potent factor concerning the development of anthelmintic resistance.

  2001cited by this paper
• Characterisation of a β-tubulin gene from the liver fluke, Fasciola hepatica

  2001cited by this paper
• Albendazole versus placebo in treatment of echinococcosis.

  2001cited by this paper
• A safe, effective, herbal antischistosomal therapy derived from myrrh.

  2001cited by this paper
• Stability and reproductive fitness of Schistosoma mansoni isolates with decreased sensitivity to praziquantel.

  2001cited by this paper
• RANDOMLY AMPLIFIED POLYMORPHIC DNA (RAPD) POLYMERASE CHAIN REACTION ASSAY FOR IDENTIFICATION OF SCHISTOSOMA MANSONI STRAINS SENSITIVE OR TOLERANT TO ANTI-SCHISTOSOMAL DRUGS

  2000cited by this paper
• Activity of closantel against adult triclabendazoleresistant Fasciola hepatica

  2000cited by this paper
• Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection

  2000cited by this paper
• Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study.

  2000cited by this paper
• Presentation and outcome of 1107 cases of schistosomiasis from Africa diagnosed in a non-endemic country.

  2000cited by this paper
• Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature.

  2000cited by this paper
• Effect of a Combination of the New Antischistosomal Drug Ro 15-5458 and Praziquantel on Different Strains of Schistosoma mansoni Infected Mice

  2000cited by this paper
• Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial.

  2000cited by this paper
• Praziquantel and the control of schistosomiasis.

  2000cited by this paper
• Praziquantel: is there real resistance and are there alternatives?

  2000cited by this paper
• Bioavailability of Praziquantel Increases with Concomitant Administration of Food

  2000cited by this paper
• The global status of schistosomiasis and its control.

  2000cited by this paper
• Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers.

  1999cited by this paper
• Mechanisms of fasciolicide action and drug resistance in Fasciola hepatica.

  1999cited by this paper
• How much human helminthiasis is there in the world?

  1999cited by this paper
• Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia.

  1999cited by this paper
• Tapeworm infection is a significant risk factor for spasmodic colic and ileal impaction colic in the horse.

  1998cited by this paper
• The USAID/Government of Egypt's Schistosomiasis Research Project (SRP).

  1998cited by this paper
• Time-response curve of oxfendazole in the treatment of swine cysticercosis.

  1998cited by this paper
• Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease.

  1998cited by this paper
• Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1.

  1998cited by this paper
• Alterations in cytochrome-c oxidase expression between praziquantel-resistant and susceptible strains of Schistosoma mansoni

  1998cited by this paper
• Efficacy of praziquantel against Schistosoma mansoni in northern Senegal.

  1998cited by this paper
• Schistosomiasis control in Brazil.

  1998cited by this paper
• An international initiative on praziquantel use.

  1998cited by this paper
• Schistosomiasis in the Senegal River Basin: before and after the construction of the dams at Diama, Senegal and Manantali, Mali and future prospects

  1997cited by this paper
• Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low.

  1997cited by this paper
• Genotoxic activity of praziquantel.

  1997cited by this paper
• Study of the efficacy of the new antischistosomal drug 10-[2-(diethylamino)ethyl]-9-acridanone-(thiazolidin-2-ylidene) hydrazone against an Egyptian strain of S. mansoni in mice.

  1997cited by this paper
• Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal.

  1997cited by this paper
• Schistosoma japonicum GSH S-transferase Sj26 is not the molecular target of praziquantel action.

  1997cited by this paper
• Pharmacokinetic study of praziquantel administered alone and in combination with cimetidine in a single-day therapeutic regimen

  1997cited by this paper
• Schistosoma mansoni: maturation rate and drug susceptibility of different geographic isolates.

  1997cited by this paper
• Enzymatic basis for the lack of oxamniquine activity in Schistosoma haematobium infections

  1997cited by this paper
• Treatment of porcine cysticercosis with oxfendazole: a dose-response trial

  1997cited by this paper
• Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs.

  1997cited by this paper
• Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel.

  1996cited by this paper
• Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya.

  1996cited by this paper
• Use of praziquantel for the control of Moniezia expansa in lambs.

  1996cited by this paper
• Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni.

  1995cited by this paper
• Antischistosomal drugs: past, present ... and future?

  1995cited by this paper
• Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni.

  1995cited by this paper
• The effect of triclabendazole ("Fasinex") on protein synthesis by the liver fluke, Fasciola hepatica.

  1995cited by this paper
• Crystal structures of a schistosomal drug and vaccine target: glutathione S-transferase from Schistosoma japonica and its complex with the leading antischistosomal drug praziquantel.

  1995cited by this paper

• Praziquantel use in aquaculture – Current status and emerging issues

  2022cites this paper
• Modulation of mice immune responses against Schistosoma mansoni infection with anti-schistosomiasis drugs: Role of interleukin-4 and interferon-gamma

  2022cites this paper
• Praziquantel for Schistosomiasis: Single-Drug Metabolism Revisited, Mode of Action, and Resistance

  2017cites this paper
• Schistosomiasis therapeutics: whats in the pipeline?

  2016cites this paper
• Uncovering the Pathogenic Landscape of Helminth (Opisthorchis viverrini) Infections: A Cross-Sectional Study on Contributions of Physical and Social Environment and Healthcare Interventions

  2016cites this paper
• New approaches for understanding mechanisms of drug resistance in schistosomes

  2013cites this paper